Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN046 plus lenvatinib vs docetaxel in advanced NSCLC after PD-(L)1
CTR20211540Phase 3Terminated
- Sponsor
- Alphamab Oncology
- Start
- Jul 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of erfonrilimab in non-small cell lung cancer (NSCLC), sponsored by Alphamab Oncology. Started Jul 2021; status: terminated.
02
Drugs
erfonrilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20211540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211540.